Diagnostic tests and prognostic indicators

Utility of flow cytometry studies in the management of patients with multiple myeloma. Paiva B et al. Curr Opin Oncol. 2016 Sep 12. [Epub ahead of print]. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Gupta R et al. Leuk Lymphoma. 2016 Sep 23:1-4. [Epub ahead of print]. Role of MRD status in relation to clinical outcomes in…

Details

Related conditions

Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Gertz MA. Am J Hematol. 2016 Sep;91(9):947-56. doi: 10.1002/ajh.24433. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Jelinek T et al. Hematol Oncol. 2016 Sep 20. doi: 10.1002/hon.2351. [Epub ahead of print]. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Falk RH et…

Details

Emerging treatments

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Yee AJ et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30375-8. doi: 10.1016/S1470-2045(16)30375-8. [Epub ahead of print]. A selective histone deacetylase inhibitor for myeloma. Pratt G et al. Lancet Oncol. 2016 Sep 16. pii: S1470-2045(16)30407-7. doi: 10.1016/S1470-2045(16)30407-7. [Epub ahead of print]. Vemurafenib in combination with cobimetinib in…

Details

Biology and genetics

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Bock F et al. Biol Blood Marrow Transplant. 2016 Sep 13. pii: S1083-8791(16)30329-9. doi: 10.1016/j.bbmt.2016.09.003. [Epub ahead of print]. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Gaballa S et al. Am J Hematol. 2016 Oct;91(10):E442-7. doi: 10.1002/ajh.24487. Epub 2016 Sep 3.…

Details

General

Advances in understanding prognosis in myeloma. Smith D et al. Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14304. [Epub ahead of print]. Stem Cell Transplantation In Multiple Myeloma. Offidani M et al. Curr Cancer Drug Targets. 2016 Sep 19. [Epub ahead of print]. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modernmultiple myeloma therapy. Voorhees PM et…

Details

Supportive care

Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Kobayashi T et al. Ann Hematol. 2016 Sep 6. [Epub ahead of print]. Mid-term outcomes after radiofrequency-targeted vertebral augmentation in the treatment of myeloma associated vertebral fractures. Ali T et al. Technol Health Care. 2016 Sep 14;24(5):745-51. doi: 10.3233/THC-161222. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile…

Details

Complications of myeloma and its treatments

Pathological Fracture In Odontoid Process In Multiple Myeloma. Demirci U et al. Turk J Haematol. 2016 Sep 23. doi: 10.4274/tjh.2016.0020. [Epub ahead of print]. Pinpointing a Factor in Myeloma Bone Disease. [No authors listed]. Cancer Discov. 2016 Sep 22. [Epub ahead of print]. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Wanchoo R et al. Clin J Am Soc Nephrol. 2016 Sep 21. pii:…

Details

Current treatments

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Garderet L et al. Haematologica. 2016 Sep 9. pii: haematol.2016.150334. [Epub ahead of print]. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Biran N et al. Blood Cancer…

Details